Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Subconjunctival Bevacizumab injection in the management of paediatric corneal neovascularisation with and without fine needle diathermy occlusion of corneal vessels: five year follow-up

Search Title by author or title

Session Details

Session Title: Cornea Medical II

Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30

Paper Time: 08:36

Venue: Hall C3

First Author: : M.Elalfy UK

Co Author(s): :    S. Hamada                    

Abstract Details


Subconjunctival Bevacizumab injection and Fine needle diathermy occlusion of corneal vessels (FND) are both established treatment modalities for corneal neovascularisation (CVas) in adults with high safety and efficacy. Paediatric CVas is a challenge in managing various inflammatory and non-inflammatory ocular surface conditions. We report long term outcomes of subconjunctival bevacizumab injection for CVas in different indications in children, with and without FND.


The treatment was offered in Great Ormond Street Hospital, London and Queen Victoria Hospital, East Grinstead, UK.


An audit was registered and patients case notes reviewed. All procedures were performed by the same eye surgeon (SH) under general anaesthesia. Indications included CVas in both inflammatory and non-inflammatory ocular surface conditions. FND was offered as an adjunct with subconjunctival Bevacizumab in corneas with mature or established CVas. All complications were documented. Serial photoslit-lamp images were taken to assess regression of CVas. Visual acuity (VA) was recorded and analysed for all eyes included.


Twenty eyes of 16 children were treated. Twelve eyes received only subconjunctival Bevacizumab, while the other eight had combined FND with Bevacizumab injection. Age ranged from 5 to 16 years. Follow up ranged 6 months to 5 years. CVas in inflammatory corneal conditions required multiple subconjunctival Bevacizumab but no eye required more than one session of FND. VA improved in all eyes treated. All eyes showed regression of CVas in response to treatment.


Subconjunctival Bevacizumab is effective in treating paediatric CVas. Combining FND is essential in treating established and mature corneal vessels.

Financial Disclosure:


Back to previous